Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 8/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699065 | 0.93 | KCNH2 (0.53) | KCNH2F10 | |
| SCHEMBL6697977 | 0.89 | KCNH2 (0.55) | KCNH2F10 | |
| SCHEMBL6696800 | 0.84 | F10 (0.57) | KCNH2F10HTTTSHRNPSR1 | |
| SCHEMBL6698024 | 0.83 | KCNH2 (0.61) | KCNH2F10 | |
| SCHEMBL6694012 | 0.78 | KCNH2 (0.56) | KCNH2F10 | |
| SCHEMBL6694023 | 0.78 | KCNH2 (0.56) | KCNH2F10 | |
| SCHEMBL6696811 | 0.78 | KCNH2 (0.55) | KCNH2F10 | |
| SCHEMBL6696815 | 0.78 | KCNH2 (0.55) | KCNH2F10 | |
| SCHEMBL6694570 | 0.76 | F10 (0.62) | F10 | |
| SCHEMBL6697387 | 0.76 | KCNH2 (0.67) | KCNH2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072860-A1 | Piperazin-2-one amides as inhibitors of factor xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072860-A1 | Piperazin-2-one amides as inhibitors of factor xa | F2, TFPI, TFPI2 | KCNH2 2157/4885MEN1 3060/4885KMT2A 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.